These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27194023)

  • 1. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial.
    Cannon JA; Shen L; Jhund PS; Anand IS; Komajda M; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2016 Aug; 18(8):1021-31. PubMed ID: 27194023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
    Komajda M; Carson PE; Hetzel S; McKelvie R; McMurray J; Ptaszynska A; Zile MR; Demets D; Massie BM
    Circ Heart Fail; 2011 Jan; 4(1):27-35. PubMed ID: 21068341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kondo T; Campbell R; Jhund PS; Anand IS; Carson PE; Lam CSP; Shah SJ; Vaduganathan M; Zannad F; Zile MR; Solomon SD; McMurray JJV
    JACC Heart Fail; 2024 Aug; 12(8):1442-1455. PubMed ID: 38904646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Kristensen SL; Jhund PS; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Cleland JGF; Carson PE; McMurray JJV
    JACC Heart Fail; 2015 Jun; 3(6):478-486. PubMed ID: 26046842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy.
    Braunschweig F; Linde C; Benson L; Ståhlberg M; Dahlström U; Lund LH
    Eur J Heart Fail; 2017 Mar; 19(3):366-376. PubMed ID: 27338764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE.
    Kristensen SL; Castagno D; Shen L; Jhund PS; Docherty KF; Rørth R; Abraham WT; Desai AS; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Eur J Heart Fail; 2020 Dec; 22(12):2370-2379. PubMed ID: 32720404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
    Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
    Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
    Haass M; Kitzman DW; Anand IS; Miller A; Zile MR; Massie BM; Carson PE
    Circ Heart Fail; 2011 May; 4(3):324-31. PubMed ID: 21350053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irbesartan in patients with heart failure and preserved ejection fraction.
    Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
    N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of QRS morphology with cardiac structure and function in patients with heart failure.
    Pellicori P; Joseph AC; Zhang J; Lukaschuk E; Sherwi N; Bourantas CV; Loh H; Clark AL; Cleland JG
    Clin Res Cardiol; 2015 Nov; 104(11):935-45. PubMed ID: 25903113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
    Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
    Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
    Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
    J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients.
    Kosztin A; Kutyifa V; Nagy VK; Geller L; Zima E; Molnar L; Szilagyi S; Ozcan EE; Szeplaki G; Merkely B
    Europace; 2016 Apr; 18(4):550-9. PubMed ID: 26116830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.